Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2010 December;56(4) > Minerva Gastroenterologica e Dietologica 2010 December;56(4):451-65

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  CONTROVERSIES IN GASTROENTEROLOGY AND LIVER DISEASES


Minerva Gastroenterologica e Dietologica 2010 December;56(4):451-65

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Treatment of chronic hepatitis B

Cornberg M., Jaroszewicz J., Manns M. P., Wedemeyer H.

Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Germany


PDF  


Approximately 350-420 million people worldwide are chronically infected with hepatitis B virus (HBV). Chronic hepatitis B can result in liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Reactivation of hepatitis B is possible in patients with inactive or resolved hepatitis B often leading to liver failure. Those sequelae may be prevented by effective antiviral therapy. Interferon alfa, pegylated interferon alfa and five direct antiviral nucleoside and nucleotide analogues are approved for the treatment of chronic hepatitis B. Still, whom to treat, which therapy regimen to use, and when to begin treatment remain the challenges in the management HBV-infected patients. This review focuses on the current treatment concepts for chronic hepatitis B.

top of page

Publication History

Cite this article as

Corresponding author e-mail

cornberg.markus@mh-hannover.de